The article by Candia et al1 represents an important installment in a rapidly evolving story. Topical glucocorticoids administered several times daily can cause a significant increase in intraocular pressure (IOP) in about one-third of the general population, with a rather substantial increase (>15 mm Hg) in about 5%.2,3 Most patients with primary open-angle glaucoma (POAG), their first-order blood relatives, and persons with diabetes mellitus also have a strong ocular hypertensive response to topical glucocorticoids.4,5 There is reasonable evidence that if treated long enough, all humans will exhibit at least some IOP increase.
Kaufman PL. Suppression and Reduction of Corticosteroid-Induced Ocular Hypertension by Anecortave in Sheep. Arch Ophthalmol. 2010;128(3):365–366. doi:10.1001/archophthalmol.2009.410
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: